molmir admin– Author –
-
Launch of a Joint Research Project to Develop Innovative Diagnostics and Targeted Therapeutics for Acquired von Willebrand Syndrome (AVWS) — Nara Medical University × molmir Inc.: Aiming to Create a Global Breakthrough in Thrombosis and Hemostasis Research —
molmir Inc. has initiated a joint research project with Nara Medical University to develop novel targeted therapeutics and diagnostic technologies for Acquired von Willebrand Syndrome (AVWS). This collaborative initiative aims to address... -
A discovery of an ALS Pathology-Inhibiting Factor ~a major step toward new therapies through Academic Collaboration~
On October 16, the latest research accomplished by the collaborative team of our CEO, Dr. Eiichiro Mori, and our scientific advisors—Dr. Tomohide Saio (Tokushima University), Dr. Kazuma Sugie (Nara Medical University), Dr. Masashi Aoki (... -
Nominated by the Medical Startups Global Acceleration Program “Direct Flight 2025”
As part of the Ministry of Health, Labour and Welfare’s commissioned initiative—the Medical Startups Global Acceleration Program “Direct Flight”—which promotes the formation of overseas networks for medical startupsour company, engaged i... -
molmir has been selected as a startup for the Nakanoshima Qross Drug Discovery and Practical Application Promotion Program Support Project
molmir, Inc. has been selected as a startup for the Nakanoshima Qross Drug Discovery and Practical Application Promotion Program Support Project, which was adopted by the Ministry of Health, Labor and Welfare's Drug Discovery Cluster Cam... -
molmir and OrganoTherapeutics announce strategic R&D collaboration~ accelerate developing therapeutics for Parkinson’s disease with 3D midbrain organoids~
molmir Inc. (based in Nara, Japan, CEO: Eiichiro Mori, M.D., Ph.D.) is proud to announce that it has entered into an agreement with OrganoTherapeutics SARL (based in Esch-sur-Alzette, Luxembourg, CEO: Jens Schwamborn, Ph.D.) for R&D ... -
molmir was awarded the MU-TECH Research and Development Grant
Mitsubishi UFJ Technology Development Foundation, MU-TECH, has nominated molmir as an entity to be subsized by the FY 2024 second research development grant. The judging committee selected 5 projects capable of delivering solution or nov... -
molmir commenced on business development toward British life science ecosystem during the JETRO supported BioUK Launchpad
molmir was nominated to participate in the J-StarX program which delegates entrepreneurs to overseas community, initiated by JETRO, Japan External Trade Organization and METI, Ministry of Economy, Trade and Industry of Japan. BioUK is an... -
molmir was awarded at Deep Tech Venture of the Year 2025
molmir was honored at the "Deep Tech Venture of the Year 2025" award program in Startup category, hosted by Leave a Nest Co., Ltd. on January 29, 2025. The ceremony recognized deep tech startups that were taking on the challenge of solvi... -
CEO Dr. Mori will pitch at the Demo Day by Rising Biotech Challenge
On November 20, 2024, Plug and Play, a partner of the Tokyo SUTEAM initiative, will hold the final presentation event, Demo Day, for the Biotech accelerator program, Rising Biotech Challenge. Demo Day will be held at Tokyo Innovation Bas... -
molmir was interviewed at the Kansai Startup Night Vol.6 by kr36
36kr, the largest Chinese tech startup media in Japan, interviewed molmir CEO Dr. Mori on July 11st at the Kansai Startup Night held by the Union of Kansai Governments. molmir represented the startups from Nara prefecture. Our ambition t...
12